П

## FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

					or Se	ection 30(h	) of th	le inves	stment	Com	pany Au	31 01 1940								
1. Name and Address of Reporting Person <sup>*</sup> O'Dowd Hugh						2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>TherapeuticsMD</u> , Inc. [ TXMD ]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
,															Officer (g below)	ive title		Other ( below)	specify	
(Last) (First) (Middle) 951 YAMATO ROAD					3. Date of Earliest Transaction (Month/Day/Year) 03/23/2022									Chief Executive Officer						
SUITE 220																				
(Street)					4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)						
BOCA RATON FL 33431														X	X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(	State)	(Zip)																	
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Trans. Date (Month/It)					Day/Year) if any		A. Deemed xecution Date, any Month/Day/Year)		, Transaction Dispos Code (Instr.		urities Acquired (A) or sed Of (D) (Instr. 3, 4 and		A) or 8, 4 and 5)	5. Amount Securities Beneficially Following Reported	Form:			7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							с	Code	v	Amount (A) or (D)		Price	Transaction(s) (Instr. 3 and 4)				(			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned   (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			le and	7. Title a Securitie Derivativ 3 and 4)	s Unde		8. Price of Derivative Security (Instr. 5)	9. Numb derivativ Securitie Benefici Owned Followir Reporte Transac	ve es ially ng d	10. Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership t (Instr. 4)	
				Code	v	(A)	(D)	Date Exerc	cisable	Exp Date	oiration e	Title		ount or ober of res		(Instr. 4)				
Restricted Stock Units	\$0.00	03/23/2022		A		2,125,000		(1	(1)		(1)	Common Stock	2,1	25 <b>,000</b> <sup>(1)</sup>	\$0.00	2,125	,000	D		

Explanation of Responses:

1. Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest in three equal installments annually beginning March 23, 2023, becoming fully vested on March 23, 2025.

Remarks:

<u>/s/ Hugh O'Dowd</u>

\*\* Signature of Reporting Person

03/28/2022 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.